CD37-binding molecules and immunoconjugates thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9447189
APP PUB NO 20120276119A1
SERIAL NO

13436528

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DEBIOPHARM INTERNATIONAL, S.A.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Deckert, Jutta Lexington, US 24 373
Park, Peter U Somerville, US 36 406
Setiady, Julianto Waltham, US 16 112

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 20, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 20, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00